Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Low serum 25-hydroxyvitamin D levels, which reflect the body’s vitamin D stores, have been reported to be associated with poor kidney outcomes. In contrast, serum 1,25-dihydroxyvitamin D [1,25(OH)₂D], the biologically active form of vitamin D rather than nutritional stores, has been less well studied, and its association with kidney prognosis remains limited. We aimed to investigate the association between baseline serum 1,25(OH)₂D levels and kidney function decline in a prospective cohort study.
We analyzed data from a single-center prospective cohort including patients with chronic kidney disease and/or heart disease. Participants were categorized into quintiles (Q1–Q5) according to serum 1,25(OH)₂D concentrations. The composite kidney outcome was defined as the first occurrence of kidney failure requiring replacement therapy (KFRT) or a ≥40% decline in estimated glomerular filtration rate (eGFR) from baseline. Multivariable Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) across quintiles, with Q3 as the reference. Restricted cubic spline (RCS) analysis was performed to evaluate the non-linear relationship, and effect modification by vitamin D receptor activator (VDRA) use was assessed using interaction terms.
A total of 975 participants were included in the analysis. During a median follow-up of 35 months, 251 participants experienced the composite kidney outcome. Compared with Q3 (27–35 pg/mL), the adjusted HRs (95% CIs) for kidney outcomes were 1.97 (1.27–3.06) for Q1 (5–19 pg/mL), 1.67 (1.06–2.62) for Q2 (20–26 pg/mL), 1.83 (1.12–2.97) for Q4 (36–46 pg/mL), and 1.81 (1.07–3.07) for Q5 (47–126 pg/mL). RCS analysis demonstrated an L-shaped association with a turning point at approximately 27 pg/mL, below which the HR rose sharply and plateaued thereafter. The association between 1,25(OH)₂D and composite kidney outcome remained consistent irrespective of VDRA use (p for interaction = 0.527).
Lower serum 1,25(OH)₂D levels were independently associated with poor kidney outcomes, showing an L-shaped dose-response relationship. The risk increased sharply below approximately 27 pg/mL, and this association was generally consistent regardless of VDRA use.
